Cargando...

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

OBJECTIVES—Recent phase III clinical trials of immunomodulatory therapies in relapsing-remitting multiple sclerosis have shown significant benefits of active treatment on relapse related end points, but effects on disability outcomes have been inconsistent. These apparent discrepancies could be due...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Liu, C., Blumhardt, L.
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Group 2000
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1736854/
https://ncbi.nlm.nih.gov/pubmed/10727480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp.68.4.450
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!